Literature DB >> 31108168

Contribution of microglial reaction to increased nociceptive responses in high-fat-diet (HFD)-induced obesity in male mice.

Ya-Jing Liang1, Shi-Yang Feng1, Ya-Ping Qi1, Kai Li1, Zi-Run Jin2, Hong-Bo Jing2, Ling-Yu Liu2, Jie Cai2, Guo-Gang Xing3, Kai-Yuan Fu4.   

Abstract

The progressive increase in the prevalence of obesity in the population can result in increased healthcare costs and demands. Recent studies have revealed a positive correlation between pain and obesity, although the underlying mechanisms still remain unknown. Here, we aimed to clarify the role of microglia in altered pain behaviors induced by high-fat diet (HFD) in male mice. We found that C57BL/6CR mice on HFD exhibited enhanced spinal microglial reaction (increased cell number and up-regulated expression of p-p38 and CD16/32), increased tumor necrosis factor-α (TNF-α) mRNA and brain-derived neurotrophic factor (BDNF) protein expression as well as a polarization of spinal microglial toward a pro-inflammatory phenotype. Moreover, we found that using PLX3397 (a selective colony-stimulating factor-1 receptor (CSF1R) kinase inhibitor) to eliminate microglia in HFD-induced obesity mice, inflammation in the spinal cord was rescued, as was abnormal pain hypersensitivity. Intrathecal injection of Mac-1-saporin (a saporin-conjugated anti-mac1 antibody) resulted in a decreased number of microglia and attenuated both mechanical allodynia and thermal hyperalgesia in HFD-fed mice. These results indicate that the pro-inflammatory functions of spinal microglia have a special relevance to abnormal pain hypersensitivity in HFD-induced obesity mice. In conclusion, our data suggest that HFD induces a classical reaction of microglia, characterized by an enhanced phosphorylation of p-38 and increased CD16/32 expression, which may in part contribute to increased nociceptive responses in HFD-induced obesity mice.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  High-fat diet; Inflammation; Microglia; Obesity; Pain hypersensitivity; Spinal cord

Year:  2019        PMID: 31108168     DOI: 10.1016/j.bbi.2019.05.026

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  5 in total

1.  Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy via central α2A adrenoceptor.

Authors:  Bin Mei; Jun Li; Zhiyi Zuo
Journal:  Brain Behav Immun       Date:  2020-10-08       Impact factor: 7.217

2.  Physical Activity Induces Nucleus Accumbens Genes Expression Changes Preventing Chronic Pain Susceptibility Promoted by High-Fat Diet and Sedentary Behavior in Mice.

Authors:  Arthur Freitas Brandão; Ivan José Magayewski Bonet; Marco Pagliusi; Gabriel Gerardini Zanetti; Nam Pho; Cláudia Herrera Tambeli; Carlos Amilcar Parada; André Schwambach Vieira; Cesar Renato Sartori
Journal:  Front Neurosci       Date:  2020-01-22       Impact factor: 4.677

3.  Microglial Activation Mediates Noradrenergic Locus Coeruleus Neurodegeneration via Complement Receptor 3 in a Rotenone-Induced Parkinson's Disease Mouse Model.

Authors:  Lu Jing; Liyan Hou; Dongdong Zhang; Sheng Li; Zhengzheng Ruan; Xiaomeng Zhang; Jau-Shyong Hong; Qingshan Wang
Journal:  J Inflamm Res       Date:  2021-04-09

4.  Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model.

Authors:  Dongdong Zhang; Sheng Li; Liyan Hou; Lu Jing; Zhengzheng Ruan; Bingjie Peng; Xiaomeng Zhang; Jau-Shyong Hong; Jie Zhao; Qingshan Wang
Journal:  J Neuroinflammation       Date:  2021-01-05       Impact factor: 8.322

5.  Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1.

Authors:  Kai Zhang; Chun Yang; Lijia Chang; Akemi Sakamoto; Toru Suzuki; Yuko Fujita; Youge Qu; Siming Wang; Yaoyu Pu; Yunfei Tan; Xingming Wang; Tamaki Ishima; Yukihiko Shirayama; Masahiko Hatano; Kenji F Tanaka; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2020-01-27       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.